Skip to content
ABEO·Nasdaq·US

Abeona Therapeutics

Abeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases. Its FDA-approved product ZEVASKYN is an autologous cell-based gene therapy for wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa, administered through qualified treatment centers. Its development portfolio also includes AAV-based gene therapies for ophthalmic diseases.

Source: SEC 10-K Mar 17, 2026

Thematic Position

ABEO

Relationship Groups

Suppliers1
Licensing2
Competitors3

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

3 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

tarifftrade restrictionssanction
Tariffs and trade restrictions risk enforcement actions and limit business with certain countries
SEC 10-KMar 17, 2026

The full regulatory passage is part of the Pro plan.